Jon Oakhill

🚀 𝐏𝐡𝐃 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐒𝐚𝐤𝐚𝐦𝐨𝐭𝐨 𝐆𝐫𝐨𝐮𝐩 – 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐔𝐧𝐝𝐞𝐫𝐩𝐢𝐧𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐓𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐀𝐌𝐏𝐊 𝐟𝐨𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐈𝐧𝐬𝐮𝐥𝐢𝐧 𝐑𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞 The major goal of the PhD project in the @Kei__Sakamoto Group is to investigate the molecular mechanism by which AMPK controls metabolic processes in skeletal muscle and liver through specific post-translational modification (PTM, such as reversible phosphorylation) and develop unique methods/strategy to modify or mimic such regulation via cutting-edge targeted protein PTM technology or small molecules in cells/tissues. Read more about the position and apply, below! 👇 bit.ly/IPPP24_Kei #phdposition

I am proud to share with you our recently published paper showing that obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2 science.org/doi/10.1126/sc…

This preprint finds a nice home @MolecularCell. We hope that the mechanistic understanding of how ADAR1 safeguards cellular dsRNAs will provide insights for therapeutic developments. #RNAediting #ADAR authors.elsevier.com/a/1hsoa3vVUPNy…

Abstract submissions for 2024 @LorneProteins, incl. the Satellite Meeting on "Ubiquitin signalling: Molecular mechanisms, biology and targeted protein degradation" are closing soon. If you work on #ubiquitin, ubiquitin-like modifiers, #PROTACs or #TPD, we want to hear from you!